Cargando…

A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline

BACKGROUND: Eravacycline is a novel fluorocycline approved for treatment of intraabdominal infections, with a broad spectrum of activity against a range of pathogens including multidrug-resistant species, including ESBL- or KPC-producing isolates. It is approved for twice-daily dosing with no need f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Hise, Nicholas, Petrak, Russell M., Skorodin, Nathan C., Fliegelman, Robert M., Anderson, Michael, Didwania, Vishal, Han, Alice, Shah, Kairav, Chundi, Vishnu, Hines, David, Roig, Ingrid, Kalra, Apoorv
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680490/ https://www.ncbi.nlm.nih.gov/pubmed/33063176 http://dx.doi.org/10.1007/s40121-020-00351-0

Ejemplares similares

Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2
por: Petrak, Russell M., et al.
Publicado: (2021)

838. Oral Vancomycin Prophylaxis Works!
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

Value and Clinical Impact of an Infectious Disease-Supervised Outpatient Parenteral Antibiotic Therapy Program
por: Petrak, Russell M., et al.
Publicado: (2016)

1420. Successful Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
por: Van Hise, Nicholas W., et al.
Publicado: (2020)

740 Hospital Avoidance Utilizing an ID Supervised OPAT Program
por: Skorodin, Nathan, et al.
Publicado: (2014)

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2
por: Petrak, Russell M., et al.
Publicado: (2021)

Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens
por: Grossman, Trudy H., et al.
Publicado: (2017)

1577. Real-World, Multicenter Experience with Eravacycline for Various Infections
por: Alosaimy, Sara, et al.
Publicado: (2020)

1270. Early Real-world Evidence in the Use of Eravacycline for the Management of Draconian Infections
por: Carr, Amy, et al.
Publicado: (2020)

An Analysis of the Novel Fluorocycline TP-6076 Bound to Both the Ribosome and Multidrug Efflux Pump AdeJ from Acinetobacter baumannii
por: Morgan, Christopher E., et al.
Publicado: (2022)

1243. Eravacycline in Bacteremia: A Case Series
por: Andrade, Justin A, et al.
Publicado: (2021)

2137. Real World Experience with Eravacycline for the Treatment of Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
por: Lim, Andy, et al.
Publicado: (2023)

Eravacycline: A Review in Complicated Intra-Abdominal Infections
por: Scott, Lesley J.
Publicado: (2019)

Correction to: Eravacycline: A Review in Complicated Intra-Abdominal Infections
por: Scott, Lesley J.
Publicado: (2019)

In vitro activity of eravacycline against common ribotypes of Clostridioides difficile
por: Bassères, Eugénie, et al.
Publicado: (2020)

1430. Eravacycline associated hypofibrinogenemia during treatment of M.abscessus
por: Rausch, Ethan, et al.
Publicado: (2022)

Mechanism of Eravacycline Resistance in Clinical Enterococcus faecalis Isolates From China
por: Wen, Zewen, et al.
Publicado: (2020)

560. Repurposing Eravacycline for the Treatment of SARS-CoV-2 Infections
por: Reig, Núria, et al.
Publicado: (2020)

Multicenter Clinical Evaluation of ETEST Eravacycline for Susceptibility Testing of Enterobacteriaceae and Enterococci
por: Blanchard, Laurine S., et al.
Publicado: (2023)

Omadacycline, Eravacycline, and Tigecycline Express Anti-Mycobacterium abscessus Activity In Vitro
por: Li, Anqi, et al.
Publicado: (2023)

Persistent SARS-CoV-2 infectivity greater than 50 days in a case series of allogeneic peripheral blood stem cell transplant recipients
por: Han, Alice, et al.
Publicado: (2021)

In Vitro Activity of Eravacycline and Comparator Antimicrobials Against 143 Strains of Bacteroides Species.
por: Citron, Diane, et al.
Publicado: (2017)

Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects
por: Newman, Joseph V., et al.
Publicado: (2019)

Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared with Healthy Subjects
por: Horn, Patrick, et al.
Publicado: (2017)

1259. Activity of eravacycline against staphylococci isolated from periprosthetic joint infections
por: Zhuchenko, Georg, et al.
Publicado: (2020)

In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis
por: Sun, Xiang, et al.
Publicado: (2021)

Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii
por: Alosaimy, Sara, et al.
Publicado: (2022)

633. Eravacycline Use in Immunocompromised Patients: Multicenter Evaluation of Clinical and Safety Endpoints
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2022)

390. Eravacycline combination therapy for severe, recurrent, or fulminant Clostridioides difficile infection
por: Morrison, Austin R, et al.
Publicado: (2022)

2255. The Use of Dalbavancin for Staphylococcus aureus Bacteremia in Persons Who Inject Drugs (PWID)
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

253 Activity of Eravacycline Against Enterobacteriaceae and Acinetobacter baumannii from New York City
por: Abdallah, Marie, et al.
Publicado: (2014)

In Vitro Synergy Testing of Eravacycline in Combination with Clarithromycin and Rifabutin against Mycobacterium abscessus Complex
por: Chew, Ka Lip, et al.
Publicado: (2021)

Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies
por: Xu, Congjuan, et al.
Publicado: (2022)

In Vitro Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria
por: Zhang, Tingting, et al.
Publicado: (2022)

Atypical Multisystem Inflammatory Syndrome in Children (MIS-C)
por: Acharya, Suchi, et al.
Publicado: (2021)

915. Global 2018 Surveillance of Eravacycline Against Gram-positive Pathogens, Including Resistant Isolates
por: Morgan, Steven, et al.
Publicado: (2020)

Novel Tet(L) Efflux Pump Variants Conferring Resistance to Tigecycline and Eravacycline in Staphylococcus Spp.
por: Wang, Nannan, et al.
Publicado: (2021)

Evaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant Acinetobacter baumannii Patient Isolates
por: Deolankar, Manas S., et al.
Publicado: (2022)

Antibacterial Activity of Eravacycline Against Carbapenem-Resistant Gram-Negative Isolates in China: An in vitro Study
por: Zou, Xuehan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b7fsii9j1k6hal1h7lntefl035